Compare Stocks → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACHLNASDAQ:HARPNASDAQ:INMBNASDAQ:SLDBNASDAQ:TCRR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHLAchilles Therapeutics$1.21-2.4%$1.12$0.74▼$1.76$49.34M1.1766,946 shs360,085 shsHARPHarpoon Therapeutics$23.01+0.1%$22.70$3.11▼$23.21$389.61M2.111.52 million shs6.62 million shsINMBINmune Bio$11.63-2.1%$12.12$5.87▼$14.74$214.10M1.9965,171 shs92,870 shsSLDBSolid Biosciences$14.25+5.0%$9.82$1.81▼$14.99$512.36M1.88328,454 shs281,354 shsTCRRTCR2 Therapeutics$1.48-5.7%$1.65$0.82▼$3.88$58.11M1.95494,777 shs3.91 million shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHLAchilles Therapeutics-2.42%-6.20%-11.03%+39.08%+35.95%HARPHarpoon Therapeutics0.00%0.00%+0.35%+101.14%+243.43%INMBINmune Bio-2.10%+0.35%-11.29%+1.57%+72.55%SLDBSolid Biosciences+5.01%+7.39%+50.00%+111.74%+258.94%TCRRTCR2 Therapeutics0.00%0.00%0.00%0.00%+1.37%Crypto Market Preps For Trillions Worth of Inflows! (Ad)Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online EventMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHLAchilles Therapeutics3.2212 of 5 stars3.05.00.00.04.10.81.3HARPHarpoon Therapeutics4.4737 of 5 stars3.25.00.04.71.14.20.0INMBINmune Bio0.8317 of 5 stars3.50.00.00.01.91.70.0SLDBSolid Biosciences3.8337 of 5 stars3.54.00.00.03.84.20.6TCRRTCR2 TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHLAchilles Therapeutics2.00Hold$11.00809.09% UpsideHARPHarpoon Therapeutics2.33Hold$27.2518.43% UpsideINMBINmune Bio3.00Buy$16.0037.58% UpsideSLDBSolid Biosciences3.00Buy$18.2528.07% UpsideTCRRTCR2 TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest TCRR, SLDB, ACHL, INMB, and HARP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2024HARPHarpoon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/18/2024SLDBSolid BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$8.00 ➝ $21.003/15/2024SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.003/14/2024SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.003/14/2024SLDBSolid BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$8.00 ➝ $20.002/26/2024HARPHarpoon TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$13.00 ➝ $23.001/16/2024HARPHarpoon TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform1/8/2024HARPHarpoon TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform1/8/2024HARPHarpoon TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$12.00 ➝ $23.001/5/2024HARPHarpoon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$23.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHLAchilles TherapeuticsN/AN/AN/AN/A$5.03 per shareN/AHARPHarpoon Therapeutics$37.34M10.43N/AN/A$1.63 per share14.12INMBINmune Bio$370K566.41N/AN/A$3.35 per share3.47SLDBSolid Biosciences$8.09M66.51N/AN/A$6.27 per share2.27TCRRTCR2 TherapeuticsN/AN/AN/AN/A$2.58 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHLAchilles Therapeutics-$71.18M-$1.89N/AN/AN/AN/A-42.33%-37.49%4/2/2024 (Estimated)HARPHarpoon Therapeutics-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/AINMBINmune Bio-$27.30M-$1.52N/A∞N/A-12,246.88%-52.26%-38.08%3/28/2024 (Confirmed)SLDBSolid Biosciences-$96.01M-$4.84N/AN/AN/AN/A-62.11%-48.99%5/9/2024 (Estimated)TCRRTCR2 Therapeutics-$151.82M-$4.20N/AN/AN/AN/A-97.81%-69.35%N/ALatest TCRR, SLDB, ACHL, INMB, and HARP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024N/AINMBINmune BioN/A-$0.44-$0.44N/AN/AN/A 3/13/2024Q4 2023SLDBSolid Biosciences-$1.01-$1.00+$0.01-$1.00N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHLAchilles TherapeuticsN/AN/AN/AN/AN/AHARPHarpoon TherapeuticsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHLAchilles Therapeutics0.028.558.55HARPHarpoon TherapeuticsN/A1.891.89INMBINmune Bio0.053.183.18SLDBSolid Biosciences0.018.948.94TCRRTCR2 TherapeuticsN/A2.962.96OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHLAchilles Therapeutics56.38%HARPHarpoon Therapeutics74.01%INMBINmune Bio12.72%SLDBSolid Biosciences81.46%TCRRTCR2 Therapeutics64.76%Insider OwnershipCompanyInsider OwnershipACHLAchilles Therapeutics5.38%HARPHarpoon Therapeutics17.00%INMBINmune Bio36.10%SLDBSolid Biosciences19.33%TCRRTCR2 Therapeutics25.01%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACHLAchilles Therapeutics23440.78 million38.59 millionNot OptionableHARPHarpoon Therapeutics5316.93 million14.05 millionOptionableINMBINmune Bio1018.02 million11.52 millionOptionableSLDBSolid Biosciences8837.76 million30.46 millionOptionableTCRRTCR2 Therapeutics13739.26 million29.44 millionNot OptionableTCRR, SLDB, ACHL, INMB, and HARP HeadlinesSourceHeadlinePoseida Therapeutics Inc Ordinary Shares PSTXmorningstar.com - February 25 at 9:43 AMDICE Therapeutics Inc.wsj.com - June 20 at 11:13 PMAdaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Companyfinance.yahoo.com - June 1 at 4:46 PMTCR2 Therapeutics Insider Trades Send a Signalbenzinga.com - May 16 at 1:36 PMRecap: TCR2 Therapeutics Q1 Earningsmsn.com - May 12 at 9:26 AM10-Q: TCR2 THERAPEUTICS INC.marketwatch.com - May 11 at 11:15 PMTCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 11 at 8:13 AMCompanies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite Riskyfinance.yahoo.com - April 15 at 12:05 PMMizuho Downgrades Tcr2 Therapeutics (TCRR)msn.com - March 25 at 7:55 PMTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho Securitiesmarkets.businessinsider.com - March 23 at 7:23 PMAnalysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)markets.businessinsider.com - March 23 at 2:23 PMTCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 23 at 9:22 AMTCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - March 23 at 9:22 AMWhat To Know About Jefferies's Downgrade of TCR2 Therapeuticsmsn.com - March 9 at 5:14 PM4 Analysts Have This to Say About TCR2 Therapeuticsmarkets.businessinsider.com - March 9 at 12:14 PMTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. Wainwrightmarkets.businessinsider.com - March 8 at 8:52 PMShareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with Adaptimmunebenzinga.com - March 6 at 7:17 PMSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. Buyoutbenzinga.com - March 6 at 7:17 PMWhy Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?investorplace.com - March 6 at 12:02 PMTCR2 Therapeutics: Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumorsfinanznachrichten.de - March 6 at 8:28 AMAdaptimmune To Combine With TCR² In All-stock Deal - Quick Factsmarkets.businessinsider.com - March 6 at 8:28 AMAdaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumorsfinance.yahoo.com - March 6 at 8:28 AMAdaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumorsfinance.yahoo.com - March 6 at 8:28 AMTCR2 Therapeutics Stock (NASDAQ:TCRR), Quotes and News Summarybenzinga.com - February 16 at 5:19 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAchilles TherapeuticsNASDAQ:ACHLAchilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.Harpoon TherapeuticsNASDAQ:HARPHarpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.INmune BioNASDAQ:INMBINmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.Solid BiosciencesNASDAQ:SLDBSolid Biosciences Inc., a life science company, engages in developing therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a next-generation gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne); AVB-202-TT, a gene therapy program for the treatment of Friedreich's ataxia; AVB-401, a gene therapy program for the treatment of BAG3-mediated dilated cardiomyopathy; and other drugs for the treatment of undisclosed cardiac diseases. It also engages in developing platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.TCR2 TherapeuticsNASDAQ:TCRRTCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.